PharmTech Drug Digest 11.20
News|Articles|June 23, 2016

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-07-06-2016
  • Volume 11
  • Issue 7

Dow Launches ETHOCEL HP

ETHOCEL HP is a solvent free advanced productivity technology for barrier membrane coating.

Dow Pharma & Food Solutions, a division of Dow Chemical Company, announced the global launch and commercial availability of ETHOCEL High Productivity (HP), a ethylcellulose polymer for multiparticulate and taste-masking applications, designed specifically for use with rotor coater systems. The product is commercially available exclusively through Colorcon Inc, as part of the Dow and Colorcon Controlled Release Alliance, Dow said in a June 21, 2016 press announcement.

Dry coating with ETHOCEL HP offers shorting coating times for barrier membranes, at higher efficiencies, and without the need for solvents. ETHOCEL HP has shown a step improvement in coating time, 70% faster than traditional solvent and aqueous spray coating systems, according to trials conducted by Dow. Removing the solvent from the coating process allows opportunities for cost reduction and improved operation safety, the company noted.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.